Abstracts tagged "B-Lymphocyte"

Abstract Number: 0729 • ACR Convergence 2023
ROCK1 Orchestrates B-cell Differentiation Under Stress
Juan Rivera-Correa¹, Sanjay Gupta¹, Edd Ricker², Danny Flores-Castro¹, Daniel Jenkins¹, Stephen Vulcano¹, Tania Pannellini¹, Matthew Miele³, Zhuoning Li³, Nahuel Zamponi⁴, Young-Bum Kim⁵, Evgenia Giannopoulou¹, Leandro Cerchietti⁴ and Alessandra Pernis¹, ¹Hospital for Special Surgery, New York, NY, ²Columbia University, New York, NY, ³Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Weill Cornell Medicine, New York, NY, ⁵Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: The mechanisms utilized by B cells to execute their differentiation programs when exposed to damaging and stressful environments, which often accompany severe infections and…
Abstract Number: 2464 • ACR Convergence 2023
B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Erin Wilfong¹, Leslie Crofford² and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Autoantibodies directed against various tRNA synthetases defines the anti-tRNA synthetase syndrome (ARS). While it is unclear if the autoantibodies are directly pathogenic, the efficacy…
Abstract Number: 0730 • ACR Convergence 2023
NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis
Giulia Frazzei¹, Jan Piet van Hamburg², Ronald van Vollenhoven² and Sander Tas³, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis, and their presence is associated with disease severity. Consequently, detailed analysis of…
Abstract Number: 2465 • ACR Convergence 2023
Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen
Lindsay Bass¹, Dena Liu¹, Alberto Cisneros², Jennifer Young-Glazer², Leslie Crofford³, Erin Wilfong² and Rachel Bonami², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
Abstract Number: 0001 • ACR Convergence 2023
Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis
Iris Lee¹, Sonam Verma², Ivana Ling², Christine Pham³ and Peggy Kendall², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University, Saint Louis, MO, ³Washington University, St. Louis, MO
Background/Purpose: Complement and B cells are implicated in the pathophysiology of rheumatoid arthritis, an autoimmune disease characterized by synovial inflammation. Loss of complement regulator CD55…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 2466 • ACR Convergence 2023
Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Eveline Van Gompel¹, Ragnhild Stålesen², Caroline Grönwall², Annika van Vollenhoven², Lena Israelsson², Ingrid Lundberg³, Vivianne Malmström², Karine Chemin⁴ and Vijay Joshua², ¹Karolinska Institutet - KU Leuven, Leuven, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
Abstract Number: 0003 • ACR Convergence 2023
Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease
Yusho Ishii¹, Aakriti Alisha Arora¹, Scott Jenks¹, Iñaki Sanz² and Arezou Khosroshahi¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disease characterized by fibrotic masses with expansion of IgG4-producing plasma cell in multiple organs such as pancreas, lacrimal…
Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Gabriel Arguelles, Lynne Mitchell, Dennis Hourcade, John Atkinson, Elisha Roberson and Alfred Kim, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0004 • ACR Convergence 2023
CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Timothy Burwell¹, Jeffrey Hall¹, Suzanne Cole², Sarah Tursi¹, Isabelle Baribaud³, Kyle Bednar¹, Naresh Kumar¹, Julie Carman¹, Navin Rao² and Edith Janssen², ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cells contribute to the development and progression of autoimmune diseases through multiple mechanisms. Consequently, modulating B cell activation, B cell effector function, and…
Abstract Number: 0925 • ACR Convergence 2023
IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus
Changming Lu, Hui-chen Hsu, Min Gao, Jose Rubio, Winn Chatham and John Mountz, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet+ double negative 2 (DN2) B cells. Here we…
Abstract Number: 2583 • ACR Convergence 2023
A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia
Klára Prajzlerová¹, Olga Kryštůfková², Nikola Kaspříková³, Nora Růžičková², Hana Hulejová¹, Petra Hánová¹, Jiri Vencovsky⁴, Ladislav Senolt⁵ and Maria Filkova², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) substantially increases the risk of developing rheumatoid arthritis (RA). The definition of individuals with arthralgia at…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0928 • ACR Convergence 2023
Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab
Keishi Fujio¹, Mineto Ota¹, Masahiro Nakano², Yasuo Nagafuchi³, Satomi Kobayashi¹, Hiroaki Hatano², Ryochi Yoshida¹, Yuko Akutsu¹, Takahiro Itamiya¹, Nobuhiro Ban⁴, Yumi Tsuchida¹, Hirofumi Shoda¹, Kazuhiko Yamamoto⁵, Kazuyoshi Ishigaki⁶ and Tomohisa Okamura⁷, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁶RIKEN, Tokyo, Japan, ⁷Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, the biological mechanisms underlying their function are poorly understood. To address this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].